Alzheimer's Disease (AD) Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-552 in Participants With Mild Alzheimer's Disease
Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or events, and may progress to noticeable memory loss, increased confusion and agitation, and eventually, loss of independence and non-responsiveness. This study will assess how safe and effective ABBV-552 is in treating symptoms of early AD. Adverse events, change in disease activity, how ABBV-552 moves through body of participants and the body response to ABBV-552 will be assessed. ABBV-552 is an investigational drug being developed for the treatment of Alzheimer's disease (AD). Study doctors put the participants in 1 of 4 groups (3 active dose groups and a placebo group), called treatment arms. Each group receives a different treatment. There is a 1 in 4 chance that participants will be assigned to placebo. Approximately 240 participants aged 50-90 years with mild AD will be enrolled in approximately 60 sites across the world. Participants will receive oral ABBV-552 or placebo capsules once daily for 12 weeks and followed for 30 days after the last dose of study drug. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02503501 -
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
|
Phase 2 | |
| Recruiting |
NCT02854033 -
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
|
||
| Completed |
NCT02681172 -
Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD
|
Phase 4 | |
| Completed |
NCT02593318 -
Trial of Oxaloacetate in Alzheimer's Disease (TOAD)
|
Phase 1 | |
| Completed |
NCT02264899 -
MEMENTO-VAScular COmponents of Dementia
|
N/A | |
| Completed |
NCT02531360 -
Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies
|
Phase 0 | |
| Recruiting |
NCT04570761 -
Effects of Auditory Brain Stimulation by "Pink Noise" on Memory Capacities in Alzheimer's Disease: Proof of Concept Study
|
N/A | |
| Not yet recruiting |
NCT05592678 -
δ in Dementia Clinical Trials
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT05558709 -
Social-cognitive Functioning: Validation of a New Neuropsychological Test
|
N/A | |
| Recruiting |
NCT05059158 -
Amyloid-β Clearance Mechanisms in Alzheimer's Disease
|
||
| Recruiting |
NCT02832921 -
Cognitive-motor Intervention Using Virtual Reality for Middle-aged Individuals at High Dementia Risk
|
N/A | |
| Completed |
NCT02370524 -
Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease
|
Phase 1 | |
| Completed |
NCT01780519 -
The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms
|
Phase 1 | |
| Completed |
NCT02103894 -
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
|
Phase 1 | |
| Completed |
NCT03802162 -
A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355
|
Phase 1 | |
| Completed |
NCT01231971 -
Alzheimer's Disease Neuroimaging Initiative 2
|
||
| Recruiting |
NCT05291234 -
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease
|
Phase 2 | |
| Recruiting |
NCT06114745 -
A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
|
Phase 1 |